Amrita Krishnan, MD

Articles

Dr. Krishnan of the Effectiveness of Teclistamab in Relapsed/Refractory Multiple Myeloma

June 22nd 2022

Amrita Krishnan, MD, discusses the effectiveness of teclistamab in relapsed/refractory multiple myeloma.

Key Takeaways From the ASH 2021 Meeting on Newly Diagnosed and Relapsed/Refractory Multiple Myeloma

January 25th 2022

Closing out her discussion on the management of newly diagnosed and relapsed/refractory multiple myeloma, Amrita Y. Krishnan, MD, shares key takeaways from the ASH 2021 Annual Meeting.

How Will Bispecific Antibodies Fit Into the Multiple Myeloma Treatment Paradigm?

January 25th 2022

Amrita Y. Krishnan, MD, considers where bispecific antibodies will fit into the multiple myeloma treatment paradigms as single-agent or combination therapy.

A Role for Bispecific Antibodies in R/R MM: Data From MonumenTAL-1 and MajesTEC-1 Studies

January 25th 2022

Insight on results from the MonumenTAL-1 and MajesTEC-1 studies, which evaluated bispecific antibodies in patients with relapsed/refractory multiple myeloma.

Treatment Options for Patients With MM at First Relapse

January 25th 2022

Expert perspective on the management of multiple myeloma at first relapse in the context of recent clinical data from the ASH 2021 Annual Meeting.

Dr. Krishnan on Key Aspects of the ELOQUENT Trials in Relapsed/Refractory Multiple Myeloma

September 11th 2019

Amrita Krishnan, MD, director of the Judy and Bernard Briskin Center for Multiple Myeloma Research and a professor in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope, discusses key aspects of the phase III ELOQUENT-2 and -3 trials in relapsed/refractory multiple myeloma.